NCT07396090 2026-02-09
Study of KRAS-Specific Vaccine in Patients With KRAS-Mutated Solid Tumors
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase NA Not yet recruiting
Clinical Trials
10 trialsNCT06349837 2025-12-17
Safety and Tolerability of LDRT Plus Concurrent Partial SBRT and Tislelizumab in Patients With Bulky Tumors
Sichuan University
Phase 1 Recruiting
NCT05978102 2025-07-23
A Dose Escalation and Dose Expansion Clinical Study of STI-7349 in Subjects With Advanced Solid Tumors
The Fourth Affiliated Hospital of Zhejiang University School of Medicine
Phase 1/2 Recruiting
NCT06541639 2025-03-18
EVM16 Injection As a Single and Combination with Tislelizumab in Solid Tumors
Peking University
Phase 1 Recruiting
NCT06032845 2025-02-27
CASTLE-11
Fudan University
Phase 2 Recruiting
NCT05582031 2023-06-07
REFIT-MSS
Translational Research in Oncology
Phase 2 Withdrawn
NCT05841134 2023-05-09
Tislelizumab Combined With Chemotherapy (CAPOX) in the Perioperative Treatment of MSI-H/dMMR Stage II or III Colorectal Cancer
The First Affiliated Hospital of Zhengzhou University
Phase 2 Not yet recruiting
NCT05699811 2023-04-28
IFNα Expressing Mesenchymal Stromal Cells for Locally Advanced/Metastatic Solid Tumors
Chinese PLA General Hospital
Phase 1/2 Recruiting
NCT05833984 2023-04-27
Safety and Efficacy of IMM01 Plus Tislelizumab in Patients With Advanced Solid Tumors and Lymphomas
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
Phase 1/2 Unknown
NCT05809336 2023-04-12
Gut Microbial Metabolites Inosine Combined With PD-1/PD-L1 Inhibitor for Patients With Malignant Advanced Solid Tumors
Beijing Friendship Hospital
Phase 2/3 Completed